USE OF 15-CETO-PROSTAGLANDINE E COMPOUNDS AS ENDOTHELINE ANTAGONISTS.

摘要

Use of a 15-keto-prostaglandin E compound represented by formula (I): (See formula) in which R is a hydrogen atom, a hydroxyl group, a C1-6 alkyl hydroxy group or a C1- alkyl group 6; A is -CH2OH, -COOH or a salt, ester or amide thereof; B is -CH2-CH2-, -CH = CH- or CH equiv CH-, Q1 and Q2 are a hydrogen atom, a halogen atom or a C1-6 alkyl group; R1 is a saturated or unsaturated bivalent C2-6 hydrocarbon moiety that is substituted or unsubstituted with halogen oxo or aryl; R2 is a saturated or unsaturated C1-14 aliphatic hydrocarbon moiety that is unsubstituted or substituted with halogen oxo, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, cycloalkyl containing 3-6 carbon atoms, aryl or an aryloxy group; a cycloalkyl containing 3-6 carbon atoms; an aryl group or an aryloxy group for the manufacture of a medicament for use in the treatment of a disease caused by an excessive production of endothelin and selected from the group consisting of Buerger's disease, Raynaud's disease, fundus disorders and diabetes .